Total Payments
$274,642
2024 Payments
$12,908
Companies
43
Transactions
580
Medicare Patients
4,643
Medicare Billing
$571,914
Payment Breakdown by Category
Other$184,492 (67.2%)
Travel$41,797 (15.2%)
Research$26,442 (9.6%)
Food & Beverage$13,854 (5.0%)
Consulting$7,940 (2.9%)
Education$116.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $145,492 | 64 | 53.0% |
| Travel and Lodging | $41,797 | 99 | 15.2% |
| Honoraria | $39,000 | 15 | 14.2% |
| Unspecified | $26,442 | 10 | 9.6% |
| Food and Beverage | $13,854 | 387 | 5.0% |
| Consulting Fee | $7,940 | 3 | 2.9% |
| Education | $116.99 | 2 | 0.0% |
Payments by Type
General
$248,200
570 transactions
Research
$26,442
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PORTOLA PHARMACEUTICALS, LLC | $162,280 | 196 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $73,764 | 90 | $0 (2024) |
| Janssen Research & Development, LLC | $18,764 | 2 | $0 (2023) |
| Eli Lilly and Company | $7,678 | 8 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $5,250 | 6 | $0 (2022) |
| Novo Nordisk AS | $966.50 | 6 | $0 (2019) |
| Eisai Inc. | $611.92 | 17 | $0 (2024) |
| UCB, Inc. | $564.10 | 36 | $0 (2024) |
| Amgen Inc. | $490.09 | 41 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $476.54 | 42 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,908 | 66 | AstraZeneca Pharmaceuticals LP ($11,362) |
| 2023 | $60,877 | 63 | AstraZeneca Pharmaceuticals LP ($40,946) |
| 2022 | $25,653 | 44 | AstraZeneca Pharmaceuticals LP ($21,441) |
| 2021 | $3,302 | 30 | Alexion Pharmaceuticals, Inc. ($2,639) |
| 2020 | $32,307 | 16 | PORTOLA PHARMACEUTICALS, LLC ($31,468) |
| 2019 | $50,486 | 132 | PORTOLA PHARMACEUTICALS, INC. ($48,762) |
| 2018 | $84,855 | 210 | PORTOLA PHARMACEUTICALS, INC. ($82,050) |
| 2017 | $4,256 | 19 | Eli Lilly and Company ($3,366) |
All Payment Transactions
580 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $14.36 | General |
| Category: NEUROLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: NEUROSCIENCE | ||||||
| 12/04/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Neuroscience | ||||||
| 12/03/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: PAIN | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $121.84 | General |
| Category: Neurology | ||||||
| 10/30/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $14.78 | General |
| Category: NEUROLOGY | ||||||
| 09/10/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Neurology | ||||||
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Rare Disease | ||||||
| 09/05/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: PAIN | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $121.85 | General |
| Category: Rare Disease | ||||||
| 08/28/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2024 | Penumbra, Inc. | Penumbra System (Device) | Food and Beverage | Cash or cash equivalent | $165.02 | General |
| Category: Neurointervention | ||||||
| 08/27/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: PAIN | ||||||
| 08/26/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Neurology | ||||||
| 08/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $34.77 | General |
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Rare Disease | ||||||
| 08/09/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: NEUROSCIENCE | ||||||
| 07/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: PAIN | ||||||
| 07/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: NEUROSCIENCE | ||||||
| 07/17/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $76.64 | General |
| Category: Neuroscience | ||||||
| 07/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: PAIN | ||||||
| 07/09/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Neurology | ||||||
| 07/09/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.63 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 42847922ALZ2001 | Janssen Research & Development, LLC | $18,764 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $3,366 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,670 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,483 | 3 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $450.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $410.00 | 1 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY TOLERABILITY AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,324 | 1,471 | $282,075 | $108,443 |
| 2022 | 16 | 1,048 | 1,290 | $269,393 | $105,249 |
| 2021 | 18 | 1,235 | 10,402 | $487,942 | $198,346 |
| 2020 | 18 | 1,036 | 8,373 | $401,941 | $159,876 |
Total Patients
4,643
Total Services
21,536
Medicare Billing
$571,914
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 291 | 391 | $85,238 | $35,201 | 41.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 106 | 106 | $44,626 | $17,175 | 38.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 103 | 104 | $43,160 | $14,271 | 33.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 107 | $31,458 | $13,017 | 41.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 56 | 58 | $23,432 | $7,984 | 34.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 60 | 76 | $16,188 | $7,158 | 44.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 197 | 197 | $16,351 | $5,793 | 35.4% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2023 | 11 | 11 | $6,490 | $2,073 | 31.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 113 | 130 | $1,820 | $1,092 | 60.0% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 62 | 64 | $2,752 | $945.92 | 34.4% |
| 82746 | Folic acid level, serum | Office | 2023 | 55 | 56 | $2,352 | $806.96 | 34.3% |
| 82306 | Vitamin d-3 level | Office | 2023 | 26 | 26 | $2,106 | $754.26 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $1,950 | $742.70 | 38.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 34 | 34 | $1,632 | $559.64 | 34.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 20 | 22 | $836.00 | $288.64 | 34.5% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 22 | 22 | $550.00 | $194.48 | 35.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 15 | 16 | $480.00 | $165.60 | 34.5% |
| 82565 | Blood creatinine level | Office | 2023 | 25 | 26 | $390.00 | $130.52 | 33.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 11 | 12 | $264.00 | $91.32 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 285 | 474 | $103,332 | $42,522 | 41.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 112 | 112 | $46,480 | $17,473 | 37.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 74 | 82 | $24,102 | $11,094 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 61 | 61 | $25,679 | $9,962 | 38.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 66 | 72 | $29,088 | $9,317 | 32.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 70 | 89 | $18,957 | $7,204 | 38.0% |
About Dr. Mauricio Concha, MD
Dr. Mauricio Concha, MD is a Neurology healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093787780.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mauricio Concha, MD has received a total of $274,642 in payments from pharmaceutical and medical device companies, with $12,908 received in 2024. These payments were reported across 580 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($145,492).
As a Medicare-enrolled provider, Concha has provided services to 4,643 Medicare beneficiaries, totaling 21,536 services with total Medicare billing of $571,914. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Sarasota, FL
- Active Since 02/06/2006
- Last Updated 10/16/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1093787780
Products in Payments
- ANDEXXA (Biological) $153,544
- ANDEXXA (Drug) $58,922
- BEVYXXA (Drug) $23,128
- Andexxa (Drug) $2,527
- APTIOM (Drug) $398.19
- Aimovig (Biological) $360.63
- Penumbra System (Device) $312.88
- Leqembi (Drug) $311.27
- Vimpat (Drug) $298.71
- Fycompa (Drug) $263.86
- AIMOVIG (Biological) $232.40
- QULIPTA (Drug) $222.57
- Kcentra (Biological) $187.38
- UBRELVY (Drug) $178.98
- Neupro (Drug) $146.82
- Epidiolex (Drug) $142.66
- WATCHMAN Access System (Device) $140.40
- INFINITY (Device) $133.21
- ELIQUIS (Drug) $125.68
- Repatha (Biological) $124.84
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Sarasota
Donald Negroski, Md, MD
Neurology — Payments: $1.8M
Neurology $1.8M
Dr. V Kassicieh, D.o, D.O
Neurology — Payments: $403,795
Neurology $403,795
Gregory Hanes, Md, MD
Neurology — Payments: $261,651
Neurology $261,651
Ricardo Gonzalez, Md, MD
Neurology — Payments: $74,673
Neurology $74,673
Dean Sutherland, Md, MD
Neurology — Payments: $67,914
Neurology $67,914
Dr. Ronald Aung-Din, M.d, M.D
Neurology — Payments: $45,214
Neurology $45,214